Document is current
Any future updates will be listed below
-
Authors
Szturz, Petr https://orcid.org/0000-0001-9705-4168
Vermorken, Jan B.
- License Information
-
More Information
Article History
Received: 11 April 2022
Revised: 29 May 2022
Accepted: 31 May 2022
First Online: 17 June 2022
Competing interests
: PS: Has had in the last 3 years or has advisory relationships with: Merck-Serono, Servier and BMS. JBV: Has had in the last 3 years or has consulting/advisory relationships with: Immunomedics, Innate Pharma, Merck-Serono, Merck Sharp & Dome Corp, PCI Biotech, Debiopharm, Cue Biopharma, Nanobiotix and WntResearch and received lecture fees from Merck-Serono, MSD, and BMS.
: Not applicable.
: Not applicable.
